Bruker Acquires Optimal Companies for Pharma PAT Software and biopharma manufacturing automation expertise and technologies 13 May 2022
Bruker Corporation has acquired Optimal Industrial Automation and Technologies, a specialist in pharma and biopharma process analytical technology (PAT), pharma manufacturing automation and quality assurance (QA) software and systems integration, based in the United Kingdom.
The Optimal biopharma tools acquisition strengthens Bruker as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies, it said.
Financial details of the acquisition were not disclosed. Optimal’s 2022 revenue is expected to be approximately $10 million.
Optimal has a focus on the automation and optimization of batch and continuous processes in the biopharma industry – from R&D to manufacturing. As an integrated PAT solutions provider, Optimal offers development, testing, deployment and support of quality-centric pharmaceutical production systems. Optimal has more than 30 years of experience in successfully delivering regulatory-compliant biopharma solutions, ranging from the development of automated control systems for process control to the market-leading, vendor-agnostic PAT knowledge management software synTQ.
Dr. Falko Busse, President of the Bruker BioSpin Group, commented: “The acquisition of Optimal is a very exciting step for Bruker as it supports more comprehensive solutions for the biopharmaceutical industry, now adding the capabilities to integrate cutting-edge systems into biopharma manufacturing processes and workflows.”
Bruker Biospin Ltd
Optimal Industrial Automation Ltd
This material is protected by MA Business copyright
See Terms and Conditions.
One-off usage is permitted but bulk copying is not.
For multiple copies
contact the sales team.